Iovance Updates IOV-LUN-202 Results and Adds Precision TIL Strategy
Iovance reported a 24.6% objective response rate in non-squamous mNSCLC, enabling a planned sBLA in 2027 and initiation of a precision TIL strategy for evaluating specific biomarker subgroups.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed